.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average consequence of 11 months, people with metastatic stomach tumors who obtained biomarker-matched treatments based on circulating cyst DNA profiling presented a more significant scientific benefit than those getting unequaled therapy.